Abstract 33P
Background
To investigate the feasibility of virtual monoenergetic images (VMIs) derived from a dual-layer detector spectral CT (SDCT) in patients with breast cancer by assessing tumor conspicuity in comparison with conventional images (CI) and to correlate tumor conspicuity on VMIS with prognostic biomarkers.
Methods
64 patients with pathologically proven benign or breast cancers (14 benign lesions and 65 breast cancers) underwent arterial and 90s delayed phase scan on a SDCT for tumor staging between June 2016 and May 2018. CI were reconstructed at 120kVp, and VMI at 40 keV (VMI40). A retrospective spectral data analysis was performed to assess the regions of interest by using CI and VMI40 on arterial and delayed images (CIART, VMI40ART, CIDE, and VMI40DE). Two radiologists independently reviewed the 4 image sets for the conspicuity score of breast lesions. For quantitative analysis, measurement of Hounsfield units (HU) of breast lesions on VMI40ART and VMI40DE was performed. Receiver operating characteristic (ROC) analysis was performed. Estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and Ki67 level were evaluated using histopathology. Statistically, conspicuity score and mean HU of malignant lesions were correlated with histological characteristics.
Results
The mean conspicuity score of malignant lesions was significantly higher compared with that of benign lesions in all image sets (P < 0.05). The area under the ROC curve of conspicuity score for malignant lesions were greatest on VMI40DE. VMI40DE yielded significantly higher mean HU of malignant lesions compared to VMI40ART (P < 0.001). Malignant lesions on VMI40ART and VMI40DE revealed significantly higher mean HU compared to those of benign lesions (P < 0.001). The conspicuity score and the mean HU on VMI40ART were significantly higher in cancers with diameter greater than 2 cm, ER negativity, PR negativity, and Ki67 positivity (P < 0.05).
Conclusions
VMI40DE is feasible to diagnose breast cancers with higher conspicuity score and better contrast enhancement compared with VMI40ART. Moreover, VMI40ART may serve as additional predictors of a poor breast cancer prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract